Dr. Andrew M. Amaranto, MD

Dr. Amaranto practices at Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health.

Dr. Amaranto's NPI, 1659538635, was assigned on May 19, 2008. Dr. Amaranto graduated from Rutgers Robert Wood Johnson Medical School in 2006. Dr. Amaranto holds New Jersey license 25MA08800300.

Dr. Amaranto's primary practice is Hackensack University Medical Center, at 30 Prospect Ave, Hackensack, NJ 07601 in Bergen County. The practice phone is (551) 996-2000.

Dr. Amaranto's primary practice is Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health. The medical group on file is Hackensack Meridian Medical Group. Dmand AI also links Dr. Amaranto to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amaranto practices. Vendor and product names are available with a free account.

Emergency medicine is Dr. Amaranto's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Dmand AI has Dr. Amaranto's licenses on file in 2 states: New Jersey and New York.

CMS data shows 332 Medicare services from Dr. Amaranto across 3 procedure codes in 2024, for 328 Medicare patients. Medicare paid $49,887 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 328 Medicare patients who saw Dr. Amaranto in 2024. The largest group is 75 to 84, with 112 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Amaranto's median patient age at 45, with 56% women.

In 2024, Dr. Amaranto wrote 91 Medicare Part D claims for 73 patients. 98% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $47 in total drug cost. In 2023, CMS named 27 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Amaranto for performance year 2024, reported as part of a group. Dr. Amaranto accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Dr. Amaranto, published from 2022 to 2023. 2022 was the busiest year, with 2. The most frequent topics are Acute Coronary Syndrome, Emergency Service, Hospital and Troponin T. Dr. Amaranto's most frequent co-authors are Leroy Elazar Rabbani, MD, Edward Hyun Suh, MD and Andrew Jeffrey Einstein, MD, PhD.

CMS Open Payments shows 1 general payment to Dr. Amaranto from 1 drug or device company in 2019. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $19.

Dr. Amaranto graduated from Rutgers Robert Wood Johnson Medical School in 2006.